Allen Cato, M.D., Ph.D.

Principal

Dr. Cato is a Principal and Co-founder of Cato BioVentures. He also is a Co-founder of Cato Research and serves as its President, Chief Executive Officer and a Director. Dr. Cato serves as a member of the Clinical Advisory Board of VistaGen Therapeutics and in senior management and/or Director roles for several of our portfolio companies, including Hemodynamic Therapeutics, and Nutritional Restart Pharmaceuticals. He has more than 30 years of experience in clinical research and new drug development and has directed or participated in the development of more than 100 INDs and NDAs. Dr. Cato's areas of expertise include the following: clinical pharmacokinetics; biostatistics; drug surveillance; pharmacoepidemiology; adverse drug reactions; clinical study design; regulatory interactions; pulmonary and pediatric medicine; and clinical research and development. Dr. Cato has published hundreds of papers, principally in the fields of clinical pharmaceutical research, cystic fibrosis, gene therapy and global drug development.